Assenagon Asset Management S.A. Caribou Biosciences, Inc. Transaction History

Assenagon Asset Management S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 24, 2024	SELL	$4.82 - $8.26 $10.8 Million - $18.4 Million	-2,231,947 Reduced 98.82%	26,592 $136,000
Q4 2023 Jan 17, 2024	SELL	$3.58 - $6.25 $1.4 Million - $2.44 Million	-390,043 Reduced 14.73%	2,258,539 $12.9 Million
Q3 2023 Nov 06, 2023	BUY	$4.08 - $8.14 $7.7 Million - $15.4 Million	1,886,484 Added 247.54%	2,648,582 $12.7 Million
Q2 2023 Jul 25, 2023	SELL	$4.04 - $5.47 $326,945 - $442,670	-80,927 Reduced 9.6%	762,098 $3.24 Million
Q1 2023 Apr 18, 2023	SELL	$4.3 - $7.78 $50,365 - $91,127	-11,713 Reduced 1.37%	843,025 $4.48 Million
Q4 2022 Jan 12, 2023	BUY	$5.57 - $11.01 $307,725 - $608,269	55,247 Added 6.91%	854,738 $5.37 Million
Q3 2022 Oct 27, 2022	SELL	$5.34 - $12.79 $1.66 Million - $3.97 Million	-310,438 Reduced 27.97%	799,491 $8.44 Million
Q2 2022 Jul 27, 2022	BUY	$5.1 - $9.74 $5.66 Million - $10.8 Million	1,109,929 New	1,109,929 $6.03 Million

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $110M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.